383 Results for "

Sclerosis

" in MedChemExpress (MCE) Product Catalog:
Products (383)

383 Results for "Sclerosis" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-P3414A
Target:  

Proteasome

Research Areas:  

Neurological Disease

Proteasome-activating peptide 1 TFA is a peptide and a potent proteasome activator. Proteasome-activating peptide 1 TFA increases the chymotrypsin-like proteasomal catalytic activity and, consequently, proteolytic rates both in vitro and in culture. Proteasome-activating peptide 1 TFA prevents protein aggregation in a cellular model of amyotrophic lateral sclerosis .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-153040
CAS No.: 1325721-55-8
Purity:  99.67%
Synonyms: Bach1-IN-1
Research Areas:  

Metabolic Disease

HPPE (compound 236) is an orally active, potential Bach1 inhibitor. Bach1 is a transcription factor of the cap'n'collar type alkaline region leucine zipper factor family (CNC-bZip) that regulates mitochondrial metabolism and reduces glucose utilization. HPPE can be used for research in psoriasis, multiple sclerosis, and COPD .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-150298
CAS No.: 2226636-04-8
Purity:  99.71%
Synonyms: CPI-818
Target:  

Itk

Research Areas:  

Inflammation/Immunology Cancer

Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8 + cells that possess enhanced T effector function .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B1060
CAS No.: 2375-03-3
Synonyms: Methylprednisolone hydrogen succinate sodium
Methylprednisolone succinate (Methylprednisolone hydrogen succinate) sodium is a prodrug of Methylprednisolone (HY-B0260) and glucocorticoid with immunosuppressant and anti-inflammatory activity. Methylprednisolone succinate sodium binds cytosolic glucocorticoid receptors, translocates to nuclei, and modulates target gene transcription. Methylprednisolone succinate sodium alters Bax, Bcl-2, occludin, and ZO-1 expression; attenuates TLR4/NF-κB signaling; suppresses proinflammatory cytokine production and immune cell activation. Methylprednisolone succinate sodium can be used for the research of intracranial haemorrhage, rheumatoid arthritis, multiple sclerosis, preterminal cancer, inflammatory conditions, shock, immediate-type hypersensitivity, acute myocardial ischemia, hypoxic heart muscle damage, and traumatic spinal cord injury .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B1900
CAS No.: 2921-57-5
Synonyms: Methylprednisolone hydrogen succinate
Methylprednisolone succinate (Methylprednisolone hydrogen succinate) is a prodrug of Methylprednisolone (HY-B0260) and glucocorticoid with immunosuppressant and anti-inflammatory activity. Methylprednisolone succinate binds cytosolic glucocorticoid receptors, translocates to nuclei, and modulates target gene transcription. Methylprednisolone succinate alters Bax, Bcl-2, occludin, and ZO-1 expression; attenuates TLR4/NF-κB signaling; suppresses proinflammatory cytokine production and immune cell activation. Methylprednisolone succinate can be used for the research of intracranial haemorrhage, rheumatoid arthritis, multiple sclerosis, preterminal cancer, inflammatory conditions, shock, immediate-type hypersensitivity, acute myocardial ischemia, hypoxic heart muscle damage, and traumatic spinal cord injury .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-128879A
CAS No.: 1281681-33-1
Purity:  98.01%
VP3.15 dihydrobromide is a highly potent, orally bioavailable, and CNS-penetrant PDE7-GSK3 dual inhibitor, with IC50 values of 1.59 μM and 0.88 μM against PDE7 and GSK3, respectively . VP3.15 dihydrobromide elevates intracellular cAMP levels, suppresses immune responses, enhances remyelination, limits excessive tau phosphorylation, and alleviates neuroinflammation and neuronal loss. VP3.15 dihydrobromide promotes oligodendrocyte precursor cell differentiation, improves in vivo remyelination, inhibits autoimmune encephalomyelitis, and mitigates germinal matrix-intraventricular hemorrhage-related brain injury, cerebral atrophy, ventricular enlargement, and cognitive impairment. VP3.15 dihydrobromide can be used in research related to multiple sclerosis and germinal matrix-intraventricular hemorrhage .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B1139
CAS No.: 3644-61-9
Target:  

Apoptosis

Research Areas:  

Neurological Disease

Tolperisone hydrochloride is a centrally acting muscle relaxant studied in neurological disorders causing pathological rhabdomyosclerosis (pyramidal tract injury, multiple sclerosis, myelopathy, encephalomyelitis), spastic paralysis, and other muscle dystonia-related Encephalopathy. Tolperisone hydrochloride also has antiviral activity .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-145990
CAS No.: 2988135-14-2
Purity:  99.86%
Synonyms: MF6
Target:  

FABP

Research Areas:  

Inflammation/Immunology

FABPs ligand 6 (MF6) is an FABP5 and FABP7 inhibitor with KD values of 874 nM and 20 nM, respectively. FABPs ligand 6 can be used for multiple sclerosis research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-13010
CAS No.: 248281-84-7
Purity:  99.46%
Synonyms: ABR-215062
Target:  

NF-κB Apoptosis

Research Areas:  

Inflammation/Immunology

Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-109520
CAS No.: 147245-92-9
Purity:  ≥98.0%
Target:  

MHC

Research Areas:  

Inflammation/Immunology Cancer

Glatiramer acetate, a synthetic analogue of myelin basic protein and an immunomodulating agent, inhibits Experimental autoimmune encephalomyelitis (EAE), and can be used for the research of multiple sclerosis. Glatiramer acetate exhibits strong and promiscuous binding to MHC molecules and consequent competition with various myelin antigens for their presentation to T cells. A further aspect of its action is potent induction of specific suppressor cells of the T helper 2 (Th2) type that migrate to the brain and lead to in situ bystander suppression .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99008
CAS No.: 2417175-94-9
Synonyms: IC14
Atibuclimab (IC14), is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates Lipopolysaccharides (HY-D1056) (LPS)-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. Atibuclimab can be used for the research of amyotrophic lateral sclerosis, sepsis, community-acquired pneumonia, or acute lung injury .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-132580
CAS No.: 2088232-70-4
Purity:  96.53%
Synonyms: BIIB067; ISIS-SOD1Rx; ISIS 333611
Target:  

SOD

Research Areas:  

Neurological Disease

Tofersen (BIIB067) is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-132580A
CAS No.: 1898254-60-8
Purity:  97.19%
Synonyms: BIIB067 sodium; ISIS-SOD1Rx sodium; ISIS 333611 sodium
Target:  

SOD

Research Areas:  

Neurological Disease

Tofersen (BIIB067) sodium is an antisense oligonucleotide and SOD1 mRNA inhibitor with an IC50 of 320 pM. Tofersen sodium mediates RNase H-dependent degradation of SOD1 mRNA to reduce SOD1 protein levels in cerebrospinal fluid and serum. Tofersen sodium downregulates cerebrospinal fluid neurofilament light chain, neurofilament heavy chain, amyloid-beta 1-40, amyloid-beta 1-42, neuropeptide Y, ubiquitin C-terminal hydrolase L1, neuropentraxins 1, 2, R, corticotropin-releasing hormone, IL-15, and serum neurofilament light chain, neurofilament heavy chain. Tofersen sodium can be used for the research of superoxide dismutase 1-associated amyotrophic lateral sclerosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-B2132
CAS No.: 61-54-1
Synonyms: 3-(2-Aminoethyl)indole~2-(3-Indolyl)ethylamine
Tryptamine is a selective, blood-brain-penetrating 5-HT4 receptor agonist (EC50=1-3 mM) and an endogenous ligand of the aryl hydrocarbon receptor (AHR) (Kd=10-50 nM). Tryptamine promotes intestinal anion secretion and fluid transport by activating G protein-coupled receptors (GPCRs) and accelerates gastrointestinal motility. Tryptamine regulates Th17/Treg balance to inhibit neuroinflammation, competitively binds to 5-HT receptors to regulate central nervous system activity, and participates in temperature regulation and spinal reflex regulation as a neuromodulator. Tryptamine can be used to study intestinal motility disorders such as functional constipation, and has shown significant efficacy in multiple sclerosis models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99113
CAS No.: 1299440-37-1
Synonyms: MEDI-551
Inebilizumab is an anti-CD19 monoclonal antibody (mAb) with enhanced antibody-dependent cell-mediated cytotoxicity against B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15381
CAS No.: 402615-91-2
Purity:  99.18%
Synonyms: FTY720 phosphate
Fingolimod phosphate (FTY720 phosphate) is an orally active sphingosine 1-phosphate (S1P) receptor agonist. Fingolimod phosphate can promote the neuroprotective effects of microglia. Fingolimod phosphate can be used for the research of multiple sclerosis and neurologic diseases .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99524
CAS No.: 1238217-55-4
Synonyms: GBR500

Target:  

Integrin

Vatelizumab (GBR500) is a monoclonal antibody that targets the α2 subunit (CD49b) of very late antigen 2 (VLA-2). Vatelizumab can be used for research on multiple sclerosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99891
CAS No.: 339086-79-2
Synonyms: Hu23F2G

Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-126361
CAS No.: 2254001-81-3
Target:  

Ser/Thr Protease PAI-1

Research Areas:  

Inflammation/Immunology

ZK824190 is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC50s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-126361A
CAS No.: 2629177-12-2
Purity:  99.61%
Target:  

Ser/Thr Protease PAI-1

Research Areas:  

Inflammation/Immunology

ZK824190 hydrochloride is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC50s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively .
loading...
    loading...